Testing the Effects of Methylphenidate on Multiple Sclerosis
Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial
We could not find results for this trial
What it found
We found no results in the registry or in papers.
This trial finished 20 months ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Methelphenidate
Placebo
- Placebo
What it measured
Main measures
Fatigue - Modified Fatigue Impact Scale
baseline, day 30 and day 68
Fatigue
Other measures (1)
Processing Speed - Symbol Digit Modalities Test
baseline, day 30 and day 68
Thinking and memory
Who could take part
MS (type not specified) · 18 to 65
Show the full criteria
Inclusion criteria
1. Diagnosis of Multiple Sclerosis 2. Age: 18-65 years old
Exclusion criteria
1. Participants must be free of: corticosteroids, cannot be currently taking modafinil, amantadine or other psychostimulants. 2. Participants must be MS relapse free at least during the previous 4 weeks. 3. Participants cannot consume more than ≧300mg of caffeine per day. 4. Thyroid disease 5. Anemia 6. Decreased vitamin D.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in daily activities. The goal of this project is to test whether methylphenidate (MP), a well-known psychostimulant, can effective treat fatigue experienced by individuals with MS. The current study will test the effect of MP on MS fatigue through a clinical trial. Every participant in the study will be exposed to both the drug and the placebo for a period of time. Both the investigators and participants will be unaware whether participants are receiving the drug or the placebo. Upon successful completion of the study, physicians will be able to evaluate the potential prescription of MP to treat fatigue in persons with MS based on solid research evidence. Importantly, MP is already an FDA approved widely used medication in multiple clinical populations.
Loading reviews and guidelines…
History
Started
Oct 2014
Main results due
Feb 2025
Finished
Mar 2025